Xiamen Amoytop Biotech Co., Ltd.
Clinical trials sponsored by Xiamen Amoytop Biotech Co., Ltd., explained in plain language.
-
New hope for adults with growth hormone deficiency: experimental drug enters mid-stage trial
Disease control Not yet recruitingThis study tests a new drug called inpegsomatropin in 36 adults with growth hormone deficiency. Participants receive either the drug or a placebo to check safety and how well it works. The goal is to see if the drug can safely replace missing growth hormone and improve body compo…
Phase: PHASE2 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New pill for fatty liver enters early human testing
Disease control Not yet recruitingThis early-stage trial tests a new oral drug called ACT500 in 24 adults with metabolic fatty liver disease (MASLD). The main goal is to check safety and how the drug moves through the body. Participants take one pill daily, and doctors monitor for side effects and measure drug le…
Phase: PHASE1 • Sponsor: Xiamen Amoytop Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC